New drug targets tough cancer mutation in early trial
NCT ID NCT06227377
First seen Jan 05, 2026 · Last updated Jun 22, 2026 · Updated 28 times
Summary
This early-stage trial tests a new drug called QTX3034, alone or with another drug (cetuximab), in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 250 participants will take part. Success could lead to better treatments for these hard-to-treat cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke University
RECRUITINGDurham, North Carolina, 27710, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10461, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Email: •••••@•••••
-
SCRI- Nashville
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START San Antonio, LLC
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sarah Cannon Research Institute (SCRI)
RECRUITINGDenver, Colorado, 80218, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCLA Hematology/Oncology
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Utah, Huntsman Cancer Center
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06511, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QTX3034 (a drug) and cetuximab (a combination drug)
What this could lead to
If this works, it could point toward a new treatment option for people with hard-to-treat cancers that have a specific KRAS mutation.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. It is small and may not lead to a proven treatment. Side effects are unknown.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.